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The increased incidence of aggressive cutaneous
squamous cell carcinoma (C-SCC) is well known
in the immunosuppressed, solid organ transplant
population. Heart and lung transplant recipients are
particularly at risk for aggressive C-SCC development
given their more intensive immunosuppression reg-
imens and older age at time of transplant.1 In organ
transplant recipients, the risk of metastasis is also
higher than that in the general population and
estimated to be approximately 7% to 8%.2,3 Here
we describe a patient who underwent bilateral lung
transplantation who, after prophylaxis with vorico-
nazole therapy, had uncontrolled, recurrent, and
ultimately metastatic C-SCC. This case report illus-
trates the aggressive nature of transplant-related
C-SCC, which may often be accelerated by
voriconazole.
We discuss the management decisions that were
made and illustrate the challenges inmanaging large,
recurrent tumors. We also briefly review the current
literature on voriconazole-associated squamous cell
carcinomas (SCCs), and propose that early, aggres-
sive surgical management may have prevented poor
outcomes.CASE
A 63-year-old white man with a history of end-
stage lung disease secondary to emphysema under-
went a bilateral lung transplant in June 2009.
Immediately after the transplant the patient was
treated with intravenous basiliximab and a 3-drug
immunosuppression regimen consisting of predni-
sone at 15 mg daily, tacrolimus at 4 mg twice daily,the Department of Dermatology, Emory University School of
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antifungal prophylaxis was also initiated at 200 mg
twice daily. The prednisone dose was weaned to 5
mg daily by the fourth month postoperatively.
In February 2011, his transplant team referred him
to the dermatology department to evaluate a large,
growing lesion of his left forearm. Physical exami-
nation found a 7.0-cm 3 5.5-cm exophytic tumor
without background actinic keratosis or field disease
(Fig 1, A). Punch biopsy of the left forearm lesion
found poorly differentiated C-SCC infiltrating to the
subcutaneous fat (Fig 1, B and C ). There was also
evidence of perineural invasion (not shown). Mohs
micrographic surgery (MMS) was performed, and the
lesion was cleared with negative margins after 2
stages. This finding was confirmed on permanent
formalin-fixed sections of the resected tissue. The
defect was subsequently repaired with a full-
thickness skin graft. At this time, voriconazole was
also discontinued, and azathioprine was decreased
to 50 mg daily with eventual discontinuation at
tumor recurrence.
In May 2011, the patient was hospitalized after a
motor vehicle accident. During that time, he was
found to have recurrence of the primary C-SCC on
the left forearm (Fig 1, D) along with newly
developed in-transit metastases to the elbow.
Positron emission tomography scan at the timeJAAD Case Reports 2015;1:S12-5.
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Fig 1. A, SCC in double-lung transplant recipient on voriconazole. There is no background
actinic keratosis or field disease. B and C, Biopsy results show poorly differentiated SCC deeply
infiltrating to subcutaneous fat on high-power view (C, inset). There was evidence of
perineural invasion (not shown). D, Recurrence of aggressive SCC 2 months after MMS with
negative margins confirmed on formalin-fixed tissue. E, Recurrence at radiation site.
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within the left upper extremity concerning for
metastases. Fine-needle aspiration was attempted
but was unsuccessful because of difficulty accessing
the lymph nodes, as the patient sustained a com-
pound fracture of the left humerus. The patient was
referred to the surgical oncology and radiation
oncology departments for further treatment. The
collective decision was to proceed with preoperative
radiation therapy before further surgical interven-
tion. In the months following, the patient was treated
with radiation (total dose, 52 Gy) to only the primary
site, to which he showed incomplete response.
Because of difficulties mobilizing his arm after his
accident, the other lesion near his elbow could not
be irradiated.
In October 2011, his recurrent tumor measured
approximately 103 83 1 cm on his left forearm, and
the tumor on his left elbow measured approximately
5 3 4 3 2 cm. He also had palpable adenopathy by
this time. The 2 tumors were surgically removed and
2 left epitrochlear nodes were biopsied. Both nodes
were positive for SCC. A complete lymph node
dissection was subsequently performed in the left
axilla; 3 of 28 lymph nodes were positive with
extranodal extension. In November and December,there was evidence of clinical recurrence in the
irradiated area, in the axilla, and 3 satellite lesions
surrounding the primary tumor site in the left fore-
arm (Fig 1, E ). All of these were resected. His
immunosuppressive medications were revised to
sirolimus at 2 mg daily (from tacrolimus). By now,
the patient also had a painful lesion on the dorsal
part of the right hand. MMS was offered for this
lesion, and the hematology/oncology department
recommended starting cetuximab/radiation therapy
for axillary disease and recurrence. However, the
patient declined further treatments. Despite medical
advice, he voluntarily discontinued all his immuno-
suppressivemedications and died as a result of septic
shock secondary to multilobar pneumonia.
DISCUSSION
This case illustrates advanced C-SCC in an
immune-suppressed double-lung transplant recip-
ient after voriconazole prophylaxis. Voriconazole is
a widely prescribed antifungal medication used for
prevention and treatment of invasive fungal in-
fections in organ transplant recipients.4 Many case
reports describe skin cancer, particularly C-SCC,
after photosensitivity reactions in both adult and
pediatric patients receiving long-term voriconazole
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pressed, including stem cell and solid organ trans-
plant recipients. The large number of reported
cases inspired several cohort studies that estab-
lished voriconazole as an independent risk factor
for the development of cutaneous malignancy in
lung transplant recipients.4,12-15
One case-control study of lung transplant recip-
ients identified long-term voriconazole (median
cumulative dose, 76 g) and residence in areas of
strong sun exposure as independent risk factors for
C-SCC.14 Another study suggests that voriconazole-
associated C-SCC was more aggressive compa-
red with nonevoriconazole-associated C-SCC.15
Although the mechanisms by which voriconazole
may predispose to skin cancer are not entirely clear,
phototoxicity associated with voriconazole has
been reported, and primary metabolite voriconazole
N-oxide may be involved.5,16 A recent review syn-
thesizes the current data on this topic.16
Currently, no guidelines exist to standardize pro-
phylactic administration of voriconazole. However,
because of the potential risk of skin cancer in long-
term voriconazole use, the US Food and Drug
Administration has altered its labeling to state that
voriconazole should be used carefully for durations
greater than 6 to 9 months, particularly among
patients with risk factors for skin cancer. In general,
for patients requiring prolonged voriconazole,
diligent skin examinations, avoidance of excess
sunlight, and liberal use of ultraviolet protectants
are advisable.
For a patient with transplant-associated C-SCC,
MMS with clear margins is the recommended
approach to achieve locoregional control.17,18 In
the transplant population, C-SCCs have a higher
propensity to recur and metastasize.3,19 Therefore,
treating C-SCCs at an early stage and achieving
locoregional control is crucial in the treatment of
these patients.20 Nodal metastases are more likely to
occur when a combination of high-risk features are
present.20 These features include size ([2 cm),
depth of invasion, poor differentiation, previous
radiation therapy, perineural invasion, and recur-
rence.17,21 This profile is consistent with that of the
patient we describe.
Adjuvant radiotherapy is often proposed for post-
surgical management when excision is incomplete,
for a nonsurgical candidate, or in the setting of
dermal metastases to improve local control and
prevent recurrence.20,22 In this patient, radiotherapy
was chosen to reduce the size of the tumor followed
by surgical extirpation. However, given the aggres-
sive nature of the tumor, radiation therapy may not
have been optimal. Particularly with high-risk,recurrent C-SCCs, expedited surgical extirpation
with wide margins, followed by radiation therapy,
may have offered a better opportunity for disease
control.
All patients exposed to voriconazole should be
educated about the increased risk of skin cancer and
should have regular dermatologic follow-up for
skin cancer screening. Physicians caring for lung-
transplant recipients should consider alternatives to
voriconazole in patients at risk for skin cancer.
Treatment for transplant-associated C-SCC should
include aggressive surgical intervention. Finally,
awareness of the patient’s quality of life and respect
for patient autonomy cannot be overlooked. The
morbidity associated with transplant-related aggres-
sive skin cancer is considerable, and we must also
respect the patient’s decision to discontinue care.
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